Nektar Therapeutics Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
Nektar Therapeutics (NKTR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 104.90% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2026-03-13
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2025 was 104.90%, a 14.39% increase from fiscal 2024.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2024 was 91.70%, a 3.73% increase from fiscal 2023.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2023 was 88.40%, a 13.48% increase from fiscal 2022.
- Nektar Therapeutics share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2022 was 77.90%, a 22.10% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month |
|---|---|
| 2025-12-31 | 104.90% 10-K · filed 2026-03-13 |
| 2024-12-31 | 91.70% 10-K · filed 2026-03-13 |
| 2023-12-31 | 88.40% 10-K · filed 2025-03-14 |
| 2022-12-31 | 77.90% 10-K · filed 2024-03-05 |
| 2021-12-31 | 63.80% 10-K · filed 2024-03-05 |
| 2020-12-31 | 64.10% 10-K · filed 2023-02-28 |
| 2019-12-31 | 62.20% 10-K · filed 2022-03-01 |
| 2018-12-31 | 61.00% 10-K · filed 2021-02-26 |
| 2017-12-31 | 54.20% 10-K · filed 2020-02-28 |
| 2016-12-31 | 51.70% 10-K · filed 2019-03-01 |
| 2015-12-31 | 50.80% 10-K · filed 2018-03-01 |
| 2014-12-31 | 51.60% 10-K · filed 2017-03-01 |
| 2013-12-31 | 61.20% 10-K · filed 2016-02-29 |
| 2012-12-31 | 62.20% 10-K · filed 2015-02-26 |
| 2011-12-31 | 63.80% 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |